Peter Schoenknecht

1.3k total citations · 1 hit paper
20 papers, 914 citations indexed

About

Peter Schoenknecht is a scholar working on Psychiatry and Mental health, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Peter Schoenknecht has authored 20 papers receiving a total of 914 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Psychiatry and Mental health, 6 papers in Molecular Biology and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Peter Schoenknecht's work include S100 Proteins and Annexins (4 papers), Stress Responses and Cortisol (3 papers) and Alzheimer's disease research and treatments (3 papers). Peter Schoenknecht is often cited by papers focused on S100 Proteins and Annexins (4 papers), Stress Responses and Cortisol (3 papers) and Alzheimer's disease research and treatments (3 papers). Peter Schoenknecht collaborates with scholars based in Germany, Netherlands and United Kingdom. Peter Schoenknecht's co-authors include Matthias L. Schroeter, Karsten Mueller, Maryna Polyakova, Katharina Stuke, Christian Sander, Sebastian Olbrich, Ulrich Hegerl, Johann Steiner, Julia Sacher and M. Schroeter and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Affective Disorders.

In The Last Decade

Peter Schoenknecht

19 papers receiving 900 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis

2014 388 citations Maryna Polyakova, Katharina Stuke et al. Journal of Affective Disorders profile →

Peers

Countries citing papers authored by Peter Schoenknecht

Since Specialization

Citations

This map shows the geographic impact of Peter Schoenknecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schoenknecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schoenknecht more than expected).

Fields of papers citing papers by Peter Schoenknecht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Schoenknecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schoenknecht. The network helps show where Peter Schoenknecht may publish in the future.

Co-authorship network of co-authors of Peter Schoenknecht

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Schoenknecht. A scholar is included among the top collaborators of Peter Schoenknecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Schoenknecht. Peter Schoenknecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increased Serum NSE and S100B Indicate Neuronal and Glial Alterations in Subjects Under 71 Years With Mild Neurocognitive Disorder/Mild Cognitive Impairment 2022 ·Frontiers in Cellular Neuroscience ·Maryna Polyakova, Karsten Mueller, Katrin Arélin, Leonie Lampe, Francisca S. Rodriguez, Tobias Luck, Jürgen Kratzsch, Karl‐Titus Hoffmann, Steffi G. Riedel‐Heller, Arno Villringer, Peter Schoenknecht, Matthias L. Schroeter	17
2	Hypothalamic volume in pedophilia with or without child sexual offense 2022 ·European Archives of Psychiatry and Clinical Neuroscience ·(unknown), (unknown), Till Amelung, Klaus M. Beier, Tillmann H.C. Krueger, Christopher Sinke, Henrik Walter, Martin Walter, Boris Schiffer, Stephanie Schindler, Peter Schoenknecht	2
3	Serum BDNF levels correlate with regional cortical thickness in minor depression: a pilot study 2020 ·Scientific Reports ·Maryna Polyakova, Frauke Beyer, Karsten Mueller, Christian Sander, A. Veronica Witte, Leonie Lampe, F.A.P. Rodrigues, Steffi G. Riedel‐Heller, Jüergen Kratzsch, Karl‐Titus Hoffmann, Arno Villringer, Peter Schoenknecht, M. Schroeter	14
4	First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression 2016 ·European Psychiatry ·Maryna Polyakova, Christian Sander, Katrin Arélin, Leonie Lampe, Tobias Luck, J. Kratzsch, (unknown), Steffi G. Riedel‐Heller, Arno Villringer, Peter Schoenknecht, M. Schroeter	3
5	First evidence for glial pathology in late life minor depression: S100B is increased in males with minor depression 2015 ·Frontiers in Cellular Neuroscience ·Maryna Polyakova, Christian Sander, Katrin Arélin, Leonie Lampe, Tobias Luck, Melanie Luppa, Jürgen Kratzsch, Karl‐Titus Hoffmann, Steffi G. Riedel‐Heller, Arno Villringer, Peter Schoenknecht, Matthias L. Schroeter	20
6	Brain-Derived Neurotrophic Factor and Antidepressive Effect of Electroconvulsive Therapy: Systematic Review and Meta-Analyses of the Preclinical and Clinical Literature 2015 ·PLoS ONE ·Maryna Polyakova, M. Schroeter, Bernet M. Elzinga, Štefan Holiga, Peter Schoenknecht, E. R. de Kloet, Marc L. Molendijk	87
7	BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis breakdown → 2014 ·Journal of Affective Disorders ·Maryna Polyakova, Katharina Stuke, (unknown), Karsten Mueller, Peter Schoenknecht, Matthias L. Schroeter	388
8	Differentiation between free and bound leptin in depressed patients 2014 ·Psychiatry Research ·Maria Strauß, Roland Mergl, Jüergen Kratzsch, Mathias Brügel, Erik Strauss, Ulrich Hegerl, Peter Schoenknecht	2
9	Internal Dose Assessment of (–)-¹⁸F-Flubatine, Comparing Animal Model Datasets of Mice and Piglets with First-in-Human Results 2014 ·Journal of Nuclear Medicine ·Bernhard Sattler, Mathias Kranz, Alexander Starke, (unknown), Cornelius K. Donat, Winnie Deuther‐Conrad, Marianne Patt, Andreas Schildan, J. T. Patt, René Smits, Alexander Hoepping, Peter Schoenknecht, Jörg Steinbach, Peter Brust, Osama Sabri	10
10	A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder 2013 ·Neuropsychiatric Disease and Treatment ·Peter Schoenknecht, (unknown), (unknown)	11
11	Serum S100B Represents a New Biomarker for Mood Disorders 2013 ·Current Drug Targets ·Matthias L. Schroeter, Julia Sacher, Johann Steiner, Peter Schoenknecht, Karsten Mueller	96
12	Accuracy of [18F]FDG PET/MR versus PET in brain imaging 2013 ·Anke Bresch, Michael Rullmann, Julia Luthardt, Peter Werner, Thies H. Jochimsen, (unknown), Peter Schoenknecht, Matthias L. Schroeter, Osama Sabri, Henryk Barthel	1
13	PET Imaging of Cerebral Nicotinic Acetylcholine Receptors (nAChRs) in Early Alzheimer’s Disease (AD) Assessed with the New Radioligand (–)-[18F]Norchloro-Fluoro-Homoepibatidine ((–)-[18F]Flubatine) 2012 ·JuSER (Forschungszentrum Jülich) ·Osama Sabri, (unknown), Jörg Steinbach, Peter Brust, (unknown), Georg‐Alexander Becker, Swen Hesse, Bernhard Sattler, Peter Schoenknecht, Gudrun Wagenknecht, René Smits, Alexander Hoepping	3
14	Hyperstable regulation of vigilance in patients with major depressive disorder 2011 ·The World Journal of Biological Psychiatry ·Ulrich Hegerl, (unknown), Sebastian Olbrich, Peter Schoenknecht, Christian Sander	87
15	Cerebrospinal Fluid Concentrations of Functionally Important Amino Acids and Metabolic Compounds in Patients with Mild Cognitive Impairment and Alzheimer’s Disease 2010 ·Neurodegenerative Diseases ·Elmar Kaiser, Peter Schoenknecht, (unknown), Wulf Hildebrandt, Ralf Kinscherf, Johannes Schröeder	50
16	Serotonin transporter (SERT) availability, body mass index (BMI) and depression 2009 ·Max Planck Digital Library ·Swen Hesse, Arno Villringer, Peter Schoenknecht, Georg‐Alexander Becker, Marianne Patt, Anke Bresch, Julia Luthardt, M Faßhauer, Peter Brust, Osama Sabri	0
17	Are Psychostimulants a Treatment Option in Mania? 2009 ·Pharmacopsychiatry ·Ulrich Hegerl, Christian Sander, Sebastian Olbrich, Peter Schoenknecht	35
18	Diffusion tensor imaging of frontal lobe white matter tracts in schizophrenia 2006 ·Annals of General Psychiatry ·Monte S. Buchsbaum, Peter Schoenknecht, Yuliya Torosjan, Randall E. Newmark, King-Wai Chu, Serge A. Mitelman, Adam M. Brickman, Lina Shihabuddin, M. Mehmet Haznedar, Erin A. Hazlett, (unknown), Cheuk Y. Tang	78
19	Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study 2005 ·Current Medical Research and Opinion ·(unknown), Bernd Ibach, Peter Schoenknecht, (unknown), Gabrielle Silver, Johannes Schröeder, R. Mielke	8
20	Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease 2000 ·Neurobiology of Aging ·Peter Schoenknecht, Johannes Schröeder, Johannes Pantel, E Werle, Tobias Hartmann, Marco Essig, K. Baudendistel, Konrad Beyreuther	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact